PD-1 expression in tumor infiltrating lymphocytes as a prognostic marker in early-stage non-small cell lung cancer
Patients with early-stage NSCLC who exhibited PD-1 expression of ≥10% on TILs had an unfavorable 10-year OS rate. These findings indicate that elevated PD-1 expression on TILs can be associated with immune evasion during the early stages of malignancy evolution in the NSCLC setting and further research is required to further delineate the role of PD-1/PD-L1 pathway on tumor immune senescence. These results underline the potential role of PD-1/PD-L1 inhibitors in the treatment of early-stage NSCLC.
Authors
- R. Guijarro (ORCID: https://orcid.org/0000-0003-2306-7796)
- Asaf Dan
- M. Angeles Montero-Fernandez
- Simon Ekman (ORCID: https://orcid.org/0000-0002-8343-6226)
- Luigi De Petris
- Ozan Aricak
- Konstantinos Rounis (ORCID: https://orcid.org/0000-0002-6643-9855)
- Cristian Ortiz‐Villalón (ORCID: https://orcid.org/0000-0002-6159-3781)
Institutions
- Karolinska University Hospital (SE)
- University of Liverpool (GB)
- Universitat de València (ES)
- Royal Liverpool University Hospital (GB)
- Karolinska Institutet (SE)
- Karolinska Development (Sweden) (SE)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2024-09-26
- DOI
- https://doi.org/10.3389/fonc.2024.1414900
- Citations
- 4
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.13